Advertisement

Topics

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline Review, H1 2015

05:00 EDT 8 Jun 2015 | BioPortfolio Reports

Recently added to the BioPortfolio report store, Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline Review, H1 2015 is a new report from Global Markets Direct published on 2015-04-28. This 100-page report is available in PDF from $2000.

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline Review, H1 2015’, provides an overview of the Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) pipeline on the basis of target, MoA, route of administration and molecule…

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Overview 8
Therapeutics Development 9
Pipeline Products for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Overview 9
Pipeline Products for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Comparative Analysis 10
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Therapeutics under Development by Companies 11
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Therapeutics under Investigation by Universities/Institutes 12
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Products under Development by Companies 16
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Products under Investigation by Universities/Institutes 18
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Companies Involved in Therapeutics Development 19
Altor BioScience Corporation 19
Bavarian Nordic A/S 20
Cold Genesys, Inc. 21
Heat Biologics, Inc. 22
Marina Biotech, Inc. 23
Oncogenex Pharmaceuticals, Inc. 24
Spectrum Pharmaceuticals, Inc. 25
TARIS BioMedical, Inc. 26
Telesta Therapeutics Inc. 27
Vakzine Projekt Management GmbH 28
Viralytics Ltd. 29
Viventia Biotechnologies Inc. 30
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Therapeutics Assessment 31
Assessment by Monotherapy Products 31
Assessment by Target 32
Assessment by Mechanism of Action 34
Assessment by Route of Administration 36
Assessment by Molecule Type 38
Drug Profiles 40
ALT-801 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
ALT-803 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
apatorsen - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
apaziquone - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
APL-1202 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Biologic for Superficial Bladder Cancer - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
CG-0070 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
CV-301 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
CVA-21 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
DAB-389EGF - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Drug for NMIBC …

For more information open Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline Review, H1 2015.

SKU: GMDHC6551IDB

Original Article: Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline Review, H1 2015

NEXT ARTICLE

More From BioPortfolio on "Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline Review, H1 2015"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Rheumatology
Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...